National Institute for Clinical Excellence (NICE) Rejects Celgene's Abraxane For Pancreatic Cancer Over Limited Benefits, Cost
Published: Sep 09, 2014
Celgene's Abraxane (nab-paclitaxel) is no better at treating metastatic pancreatic cancer than currently available treatments - but it is more expensive than them, according to NICE.
In draft guidance on the drug the UK's cost-effectiveness watchdog said Abraxane's cost did not justify its “limited benefit” and therefore it should not be funded by the NHS.
NICE chief executive Sir Andrew Dillon noted that the development of new treatments for pancreatic cancer has been very limited in recent years.
Help employers find you! Check out all the jobs and post your resume.